|
A Novel Needle-Based X-Ray System
|
5R44CA112683-03
|
$380,000
|
Gutman, George
|
ADVANCED X-RAY TECHNOLOGY, INC.
|
|
SBIR PHASE I: ANTIBODY ARRAY FOR CANCER DETECTION
|
N43CN700065-000
|
$150,000
|
BOCHKARIOV, DMITRY
|
ADVANSTA INC
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
1R44CA124032-01A1
|
$101,130
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
An Exploration of the Determinants that Impact Breast and Cervical Cancer Control
|
1R03CA132550-01
|
$50,000
|
English, Kevin
|
ALBUQUERQUE AREA INDIAN HEALTH BOARD
|
|
Integrated Technology for microRNA-based Diagnostic Assays
|
1R43CA128123-01
|
$328,413
|
LATHAM, GARY
|
AMBION DIAGNOSTICS, INC.
|
|
Young Minority Scientists in the Field of Cancer
|
5R13CA040577-22
|
$89,489
|
CLARKSON, BAYARD
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
RADIATION THERAPY ONCOLOGY GROUP
|
3U10CA021661-32S1
|
$300,000
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
RADIATION THERAPY ONCOLOGY GROUP
|
5U10CA021661-32
|
$8,875,198
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Community Clinical Oncology Program Research Base
|
5U10CA037422-20
|
$1,483,085
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
RTOG Tissue Bank
|
5U24CA114734-03
|
$793,043
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
American College of Radiology Imaging Network
|
5U01CA080098-09
|
$10,637,601
|
HILLMAN, BRUCE
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Radiation Therapy Oncology Group-Statistical Center
|
5U10CA032115-26
|
$1,038,338
|
Sadek, Ramses
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
QUALITY RESEARCH IN RADIATION ONCOLOGY: ACR PCS
|
5R01CA065435-09
|
$778,031
|
WILSON, JESSE
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Orthotopic models of tumor angiogenesis and blood flow
|
5R44CA099258-03
|
$374,848
|
YANG, MENG
|
ANTICANCER, INC.
|
|
Dual-color tumor-host imaging models
|
5R44CA103563-03
|
$375,784
|
YANG, MENG
|
ANTICANCER, INC.
|
|
Alkylating Vitamin D Derivative
|
1R41CA126317-01A1
|
$258,398
|
CASTOR, TREVOR
|
APHIOS CORPORATION
|
|
Investigating intervention opportunities for prostate cancer patients and partner
|
1R03CA128475-01
|
$72,711
|
COON, DAVID
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Portable Imaging Device for Prostate Cancer Detection
|
5R44CA082620-05
|
$1,000,000
|
Sarvazyan, Armen
|
ARTANN LABORATORIES, INC.
|
|
Bay Area Tumor Institute CCOP
|
2U10CA045461-18
|
$480,000
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
Targeting Relaxin Signaling in Prostate Cancer
|
1R21CA118362-01A1
|
$180,000
|
Agoulnik, Alexander
|
BAYLOR COLLEGE OF MEDICINE
|
|
Molecular Mechanisms by which Rexinoids Prevent BRCA
|
5R01CA078480-10
|
$337,707
|
BROWN, POWEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Prostate Cancer
|
3P50CA058204-13S1
|
$1,124,001
|
ITTMANN, MICHAEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Novel Inhibitor of Stat3 for Prostate Cancer Therapy
|
5R01CA104035-03
|
$280,899
|
JING, NAIJIE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
1P30CA125123-01
|
$1,500,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-01S1
|
$111,700
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Biochemical Analysis of the BRCA1 Protein Complex
|
5R01CA084199-08
|
$268,278
|
QIN, JUN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mesenchymal Derived Growth Factors in Prostatic Cancer
|
5R01CA058093-14
|
$256,863
|
ROWLEY, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Co-evolution of the Reactive Microenvironment in Prostate Cancer Progression
|
5U54CA126568-02
|
$700,401
|
ROWLEY, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Enhancement of Dendritic Cells for Improved Immunotherapy
|
5R01CA120411-02
|
$258,529
|
SPENCER, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mechanisms of Progression in Oncogene-Incuded Prostate Cancer
|
2R01CA050588-18A2
|
$324,883
|
Thompson, Timothy
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mechanisms of Metastasis in Experimental Prostate Cancer
|
5R01CA068814-12
|
$289,043
|
Thompson, Timothy
|
BAYLOR COLLEGE OF MEDICINE
|
|
Reversal of regulatory T cell function in prostate cancer
|
5R01CA121191-02
|
$258,529
|
Wang, Rongfu
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targets of Vitamin D Receptor Action in Prostate
|
5R01CA107691-04
|
$292,538
|
Weigel, Nancy
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of Mitochondrial DNA Alterations in Cancer
|
5R01CA100023-04
|
$291,567
|
Wong, Lee-Jun
|
BAYLOR COLLEGE OF MEDICINE
|
|
Soy Isoflavone Supplementation and Mammographic Density in Postmenopausal Women
|
5R03CA121879-02
|
$75,007
|
WONG, WILLIAM
|
BAYLOR COLLEGE OF MEDICINE
|
|
Virginia Mason Community Clinical Oncology Program
|
3U10CA035192-24S1
|
$80,000
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-24
|
$391,000
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Targeting AR-NCoR Interaction in Prostate Cancer
|
1R01CA111803-01A2
|
$323,000
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The Role of PTEN and the PI3K Pathway in Prostate Cancer
|
2P01CA089021-06A1
|
$2,125,652
|
CANTLEY, LEWIS
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Choline Metabolism in Prostate Cancers: Response to Dietary Soy Phytochemicals
|
1R21CA130013-01A1
|
$198,280
|
GASTON, SANDRA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Prostate MRI and MRS: Correlations with Gene Expression
|
5R21CA116866-02
|
$125,453
|
GASTON, SANDRA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Characterization of Prostate Cancer with 3T MR
|
5R01CA116465-02
|
$367,769
|
ROFSKY, NEIL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Survivor QOL/Spouse Satisfaction after Prostate Therapy
|
3R01CA095662-05S1
|
$222,647
|
SANDA, MARTIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr
|
5U01CA113913-03
|
$836,628
|
SANDA, MARTIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Immediate Early Genes of Herpes Simplex Virus
|
5R01CA020260-31
|
$432,063
|
SCHAFFER, PRISCILLA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The function of RhoBTB proteins
|
5R01CA113559-02
|
$293,000
|
Soltoff, Stephen
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Parental metabolic status and offspring cancer risks
|
1R03CA130131-01
|
$85,000
|
ZHOU, JIN-RONG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Synergy between phytochemicals for prostate cancer prevention
|
1R03CA130133-01
|
$85,000
|
ZHOU, JIN-RONG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Oldenlandia diffusa for prostate cancer treatment
|
1R21CA133865-01A2
|
$170,000
|
ZHOU, JIN-RONG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A novel biotherapeutic treatment for prostate cancer
|
1R43CA130228-01
|
$145,306
|
CHOI, ANTHONY
|
BEXION PHARMACEUTICALS, INC.
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|